Key Record Dates Identifier: NCT03425643
Brief Title: Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

First Submitted : February 2, 2018
First Submitted that Met QC Criteria : February 2, 2018
First Posted : February 7, 2018

Last Update Submitted that Met QC Criteria : September 15, 2021
Last Update Posted : September 16, 2021